<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04883125</url>
  </required_header>
  <id_info>
    <org_study_id>MD/17.12.30</org_study_id>
    <nct_id>NCT04883125</nct_id>
  </id_info>
  <brief_title>Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment</brief_title>
  <official_title>Potential Utility of Peroxisome Proliferator-activated Receptor Gamma Agonists in the Eradication of Chronic Myeloid Leukemia Stem Cells: Myth or Truth?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of patients response and expression levels of CITED2 and HIF2a genes on adding&#xD;
      pioglitazone to imatinib therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible denovo CML patients will be treated by combination drug therapy of imatinib 400 mg&#xD;
      plus pioglitazone (15 - 30mg).They will be on follow up for their complete blood count (CBC),&#xD;
      chemistry profile and random blood sugar every 2 weeks. After 3, 6 and 12 months of treatment&#xD;
      the patients response will be evaluated and compared with the obtained responses of a&#xD;
      historical control group. Assessment of the hypoxia induced factor 2 alpha (HIF2a) gene and&#xD;
      CBP/p300-interacting transactivator with glutamic acid (E) and aspartic acid (D)-rich tail 2&#xD;
      (CITED2) gene expression levels before and after 6 months of treatment will be additionally&#xD;
      evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">April 15, 2021</completion_date>
  <primary_completion_date type="Actual">April 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of major molecular response(MMR) at 12 months</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of patients obtaining MMR at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of treatment on the expression levels of stemness genes</measure>
    <time_frame>6 months</time_frame>
    <description>Follow up the expression of CITED2 and HIF2a genes pattern</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of treatment on the rate of transformation</measure>
    <time_frame>1 years</time_frame>
    <description>Progression into accelerated or blastic phases</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Chronic Myelogenous Leukemia, BCR-ABL Positive</condition>
  <condition>CML, Chronic Phase</condition>
  <arm_group>
    <arm_group_label>Interventional no</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with both drugs ( imatinib and pioglitazone)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Historical control (treated with imatinib only)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone 15mg</intervention_name>
    <description>pioglitazone (7.5-30 mg) once daily plus imatinib 400 mg 6 months</description>
    <arm_group_label>Interventional no</arm_group_label>
    <other_name>Imatinib 400mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  CML cases (BCR-ABL1 positive)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Accelerated or blastic crisis&#xD;
&#xD;
          -  Atypical CML (BCR-ABL1 negative)&#xD;
&#xD;
          -  Chronic myelomonocytic leukemia (CMML)&#xD;
&#xD;
          -  Pregnant or breastfeeding females.&#xD;
&#xD;
          -  Patients with severe organ dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed N. Mabed, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Oncology Center Mansoura University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Mansoura</city>
        <state>Dakahlia</state>
        <zip>35511</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>May 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Basma Atef</investigator_full_name>
    <investigator_title>Assistant lecturer of Hematology (Internal medicine department)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

